RDY
· Pharmaceuticals
Dr. Reddy's Laboratories
$13.52
+0.07 (+0.52%)
Financial Highlights (FY 2026)
Revenue
29.49T
Net Income
5.11T
Gross Margin
67.0%
Profit Margin
17.3%
Rev Growth
+14.9%
D/E Ratio
0.14
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | |
|---|---|---|
| Gross Margin | 67.0% | 67.0% |
| Operating Margin | 21.0% | 18.9% |
| Profit Margin | 17.3% | 16.5% |
Income Statement
| FY 2026 | FY 2025 | |
|---|---|---|
| Revenue | 29.49T | 25.68T |
| Gross Profit | 19.75T | 17.20T |
| Operating Income | 6.18T | 4.84T |
| Net Income | 5.11T | 4.00T |
| Gross Margin | 67.0% | 67.0% |
| Operating Margin | 21.0% | 18.9% |
| Profit Margin | 17.3% | 16.5% |
| Rev Growth | +14.9% | +14.9% |
Balance Sheet
| FY 2026 | FY 2025 | |
|---|---|---|
| Total Debt | 61.87B | 61.87B |
| Total Equity | 443.83B | 443.83B |
| D/E Ratio | 0.14 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | |
|---|---|---|
| EBITDA | 8.03T | 6.64T |
| Free Cash Flow | — | — |